<DOC>
	<DOC>NCT02216071</DOC>
	<brief_summary>The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex®, Alcon) in the treatment of acute otitis externa (AOE) when administered twice daily for 7 days.</brief_summary>
	<brief_title>Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1. Male or female, 6 months of age and over; 2. Clinically documented AOE consistent with the diagnostic guidelines of the American Academy of OtolaryngologyHead and Neck Surgery Foundation in 1 or both ears; 3. Inflammation and/or edema ≥2 on the AOE scale, and otorrhea and/or tenderness present; 4. AOE of &lt;4 weeks duration; 5. Intact tympanic membrane(s) in the treated ear(s); 6. Willingness to refrain from swimming through the TOC/ Visit 5; 7. For subjects with AOE associated with hearing aid use, willingness to discontinue the use of hearing aid(s) in the affected ear(s) through the TOC/Visit 5; 8. Ability to complete the study in compliance with the protocol; 9. For adult subjects, ability to understand and provide written informed consent; and 10. For pediatric subjects, a parent or legal guardian has provided written informed consent; and 11. For children age 6 and above, ability to understand and provide assent according to institutional requirements. 1. Acute or chronic suppurative otitis media; 2. Posttympanostomy tube acute otorrhea; 3. Malignant otitis externa; 4. Suspected or overt fungal or viral ear infection; 5. Congenital abnormalities or obstructive bony exostoses of the external auditory canal of the treated ear(s); 6. Seborrheic dermatitis or other dermatologic conditions of the external auditory canal of the treated ear(s) which could confound evaluation; 7. Mastoiditis or other suppurative infectious or noninfectious disorders of the treated ear(s); 8. Malignant tumors of the external auditory canal of the treated ear(s); 9. History of otologic surgery of the treated ear(s), with the exception of tympanic membrane surgery &gt;6 months prior to Baseline; 10. Four or more episodes of otitis externa (OE) in the previous year; 11. Uncontrolled diabetes mellitus; 12. Immunosuppressive disorder, including known Human Immunodeficiency Virus infection; 13. Renal insufficiency; 14. Hepatitis or hepatic insufficiency; 15. Receipt of systemic antibiotic concurrently or within 72 hours prior to Baseline; 16. Receipt of topical otic antibiotic within 24 hours prior to Baseline; 17. Use of systemic corticosteroid concurrently or within 30 days prior to Baseline; 18. Use of topical otic corticosteroids concurrently or within 7 days prior to Baseline; 19. Concurrent use of systemic or topical otic nonsteroidal or other antiinflammatory drugs; 20. Use of topical vinegar, alcohol, or other astringent otic preparations concurrently or within 24 hours prior to Baseline; 21. Pregnancy, planned pregnancy, or lactation; 22. Known sensitivity or intolerance to quinolone antibacterial agents; 23. Previous participation in this trial; 24. Participation in another investigational drug or vaccine trial concurrently or within 30 days; or 25. Significant acute or chronic medical, neurologic, or psychiatric illness in the subject or parent/guardian that, in the judgment of the Principal Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>